ReviewCardiovascular diabetology2016
Glucagon and heart in type 2 diabetes: new perspectives.
Review in Cardiovascular diabetology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 82 citations in OpenAlex.
- Empagliflozin reduces blood pressure and uric acid in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.Journal of human hypertension · 2019Pooled it
- Exenatide and glucagon co-infusion increases myocardial glucose uptake and improves markers of diastolic dysfunction in adults with type 2 diabetes.Scientific reports · 2025Trial
- Trial
- Endotrophin is a risk marker of complications in CANagliflozin cardioVascular Assessment Study (CANVAS): a randomized controlled trial.Cardiovascular diabetology · 2022Trial
- Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial.BMJ open diabetes research & care · 2021Trial
- Tofogliflozin decreases body fat mass and improves peripheral insulin resistance.Diabetes, obesity & metabolism · 2018Trial
- Intra- and inter-subject variability for increases in serum ketone bodies in patients with type 2 diabetes treated with the sodium glucose co-transporter 2 inhibitor canagliflozin.Diabetes, obesity & metabolism · 2018Trial
- Endocrine and metabolic alterations in response to systemic inflammation and sepsis: a review article.Molecular medicine (Cambridge, Mass.) · 2025Review
- SGLT2 inhibition improves coronary flow velocity reserve and contractility: role of glucagon signaling.Cardiovascular diabetology · 2024Article
- Glucagon-Like Peptide Receptor-1 Agonists Used for Medically-Supervised Weight Loss in Patients With Hip and Knee Osteoarthritis: Critical Considerations for the Arthroplasty Surgeon.Arthroplasty today · 2024Article
- Correlation between islet α cell function and peripheral neuropathy in patients with type 2 diabetes mellitus.Clinics (Sao Paulo, Brazil) · 2024Article
- Glucagon and Its Receptors in the Mammalian Heart.International journal of molecular sciences · 2023Review
- Evidence for a lack of inotropic and chronotropic effects of glucagon and glucagon receptors in the human heart.Cardiovascular diabetology · 2023Article
- Glucagon and exenatide improve contractile recovery following ischaemia/reperfusion in the isolated perfused rat heart.Physiological reports · 2023Article
- Hyperglucagonemia in Pediatric Adiposity Associates With Cardiometabolic Risk Factors but Not Hyperglycemia.The Journal of clinical endocrinology and metabolism · 2022Article
- The Mystery of Diabetic Cardiomyopathy: From Early Concepts and Underlying Mechanisms to Novel Therapeutic Possibilities.International journal of molecular sciences · 2021Review
- Article
- Proglucagon-Derived Peptides as Therapeutics.Frontiers in endocrinology · 2021Review
- The promise and problems of metabolic-based therapies for heart failure.Interventional cardiology · 2021Article
- Minireview: are SGLT2 inhibitors heart savers in diabetes?Heart failure reviews · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Increased levels of glucagon in type 2 diabetes are well known and, until now, have been considered deleterious. However, glucagon has an important role in the maintenance of both heart and kidney function. Moreover, in the past, glucagon has been therapeutically used for heart failure treatment. The new antidiabetic drugs, dipeptidyl peptidase-4 inhibitors and sodium-glucose co-transporter-2 inhibitors, are able to decrease and to increase glucagon levels, respectively, while contrasting data have been reported regarding the glucagon like peptide 1 receptors agonists. The cardiovascular outcome trials, requested by the FDA, raised some concerns about the possibility that the dipeptidyl peptidase-4 inhibitors can precipitate the heart failure, while, at least for empagliflozin, a positive effect has been shown in decreasing both cardiovascular death and heart failure. The recent LEADER Trial, showed a significant reduction of cardiovascular death with liraglutide, but a neutral effect on heart failure. A possible explanation of the results with the DPPIV inhibitors and empagliflozin might be related to their divergent effect on glucagon levels. Due to unclear effects of glucagon like peptide 1 receptor agonists on glucagon, the possible role of this hormone in the Leader trial remains unclear.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.